STAAR Surgical is trading at $23.36, down 5.27%, amid lingering investor concerns after second-quarter results.
- No new company-specific announcement was identified for August 20, 2026; revenue reached $93.5 million, while coverage described sentiment as underwhelmed.
- Stifel lowered its price target to $28 from $31 on China concerns, maintaining a Hold rating.
- Broader risk-off conditions are adding pressure, with major U.S. indexes down more than 0.5% as Treasury yields rise; healthcare outperforms, so sector strength does not explain the decline.